Alpa Laboratories' financial performance shows a mixed trend. Compounded profit growth is strong over the long term, but sales growth is inconsistent. Quarterly sales and profit show volatility, and OPM fluctuates. Reliance on other income is increasing.

Compounded sales growth has fluctuated, indicating inconsistency. Compounded profit growth also shows variability. Quarterly sales have fluctuated significantly, with YOY sales growth ranging from -29% to 139%. OPM has also been volatile, ranging from -42.02% to 31.62%. This inconsistency in sales and profitability indicates potential challenges in maintaining stable financial performance. The increasing reliance on other income to bolster net profit suggests that core operations may not be consistently profitable. This dependence on non-operating income can introduce uncertainty and affect the sustainability of overall profitability.

The company demonstrates good capital efficiency with improving ROCE and ROE. The cash conversion cycle presents a mixed view.

ROCE has steadily improved, indicating better utilization of capital employed. ROE has also shown improvement over the years. The cash conversion cycle has fluctuated, with an average of 158 days between 2014 and 2019, decreasing to 97 days in 2020, before increasing again to 147 days in 2025. This inconsistency suggests potential inefficiencies in working capital management.

Alpa Laboratories exhibits good financial health with controlled debt.

Borrowings have decreased significantly over the years, indicating effective debt management. The company's debt-to-equity ratio is low, reflecting a conservative approach to leverage. The interest coverage ratio is high, indicating that the company can comfortably cover its interest obligations with its operating profit. Overall, the company's financial health appears stable and prudently managed.

Working capital management shows inefficiencies with increasing debtor days and long working capital cycles.

Debtor days have fluctuated, increasing from 173 days (2014-2016) to 152 days in 2025, indicating potential issues in collecting receivables promptly. Inventory days have decreased from 141 days (2014-2016) to 92 days in 2025, showing improvement in inventory management. Payable days have decreased, which could indicate less favorable terms with suppliers. The cash conversion cycle has remained relatively stable, averaging around 150 days, suggesting consistent but not highly efficient working capital management.

There is no specific data available on off-balance sheet exposure quantification.

There is no specific data available on contingent liability evaluation.

There is no specific data available on foreign exchange or interest rate exposure.